{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:28:38Z","timestamp":1787509718164,"version":"build-2736575974"},"reference-count":53,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Fabry disease is classified as a rare X-linked disease caused by a complete or partial defect of enzyme alpha-galactosidase, due to GLA gene mutations. This disorder leads to intracellular globotriaosylceramide (Gb3) deposition associated with increased Gb3 plasma levels. Most of the symptoms of the disease, involving kidneys, heart and nervous system, result from this progressive Gb3 deposition. The incidence is estimated in 1\/50,000 to 1\/117,000 in males. Fabry nephropathy begins with microalbuminuria and\/or proteinuria, which, in the classic form, appear from childhood. Thus, a progressive decline of renal function can start at a young age, and evolve to kidney failure, requiring dialysis or renal transplantation. Enzyme replacement therapy (ERT), available since 2001 for Fabry disease, has been increasingly introduced into the clinical practice, with overall positive short-term and long-term effects in terms of ventricular hypertrophy and renal function. Kidney transplantation represents a relevant therapeutic option for Fabry nephropathy management, for patients reaching end-stage renal disease, but little is known about long-term outcomes, overall patient survival or the possible role of ERT after transplant. The purpose of this review is to analyze the literature on every aspect related to kidney transplantation in patients with Fabry nephropathy: from the analysis of transplant outcomes, to the likelihood of disease recurrence, up to the effects of ERT and its possible interference with immunosuppression.<\/jats:p>","DOI":"10.3390\/medicina56060284","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T05:02:24Z","timestamp":1591938144000},"page":"284","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Kidney Transplant in Fabry Disease: A Revision of the Literature"],"prefix":"10.3390","volume":"56","author":[{"given":"Irene","family":"Capelli","sequence":"first","affiliation":[{"name":"Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Aiello","sequence":"additional","affiliation":[{"name":"Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gasperoni","sequence":"additional","affiliation":[{"name":"Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Comai","sequence":"additional","affiliation":[{"name":"Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Corradetti","sequence":"additional","affiliation":[{"name":"Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ravaioli","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Transplantation, S. Orsola\u2014Malpighi Hospital, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Biagini","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, S. Orsola-Malpighi University Hospital, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-6869","authenticated-orcid":false,"given":"Claudio","family":"Graziano","sequence":"additional","affiliation":[{"name":"Unit of Medical Genetics, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[{"name":"Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_2","first-page":"296","article-title":"Fabry Nephropathy: An Evidence-Based Narrative Review","volume":"43","author":"Paniagua","year":"2018","journal-title":"Kidney Blood Press Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Klingelh\u00f6fer, D., Braun, M., Seeger-Zybok, R.K., Quarcoo, D., Br\u00fcggmann, D., and Groneberg, D.A. (2020). Global research on Fabry\u2019s disease: Demands for a rare disease. Mol. Genet. Genomic Med.","DOI":"10.1002\/mgg3.1163"},{"key":"ref_5","first-page":"100562","article-title":"Newborn screening for Fabry disease in the western region of Japan","volume":"22","author":"Sawada","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G > A (IVS4+919G > A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pan, X., Ouyang, Y., Wang, Z., Ren, H., Shen, P., Wang, W., Xu, Y., Ni, L., Yu, X., and Chen, X. (2016). Genotype: A Crucial but Not Unique Factor Affecting the Clinical Phenotypes in Fabry Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161330"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase Alfa and Kidney Dysfunction in Fabry Disease","volume":"20","author":"West","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","article-title":"Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: A longitudinal cohort study","volume":"34","author":"Madsen","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1016\/j.transproceed.2005.11.021","article-title":"Kidney transplantation improves survival and is indicated in Fabry\u2019s disease","volume":"37","author":"Inderbitzin","year":"2005","journal-title":"Transplant. Proc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/jhg.2016.78","article-title":"Long-term enzyme replacement therapy for Fabry disease: Efficacy and unmet needs in cardiac and renal outcomes","volume":"61","author":"Kim","year":"2016","journal-title":"J. Hum. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-77-2-195","article-title":"Reversal of an inborn sphingolipidosis (Fabry\u2019s disease) by kidney transplantation","volume":"77","author":"Philippart","year":"1972","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJM197212142872402","article-title":"Enzyme replacement therapy by renal allotransplantation in Fabry\u2019s disease","volume":"287","author":"Clarke","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"ref_22","first-page":"1499","article-title":"Fabry\u2019s disease: Two patients improved by fetal liver cells (author\u2019s transl)","volume":"8","author":"Touraine","year":"1979","journal-title":"Nouv. Presse Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1097\/TP.0000000000002257","article-title":"Persistent Alpha-galactosidase A Deficiency After Simultaneous Liver-kidney Transplantation in a Patient with Fabry Disease","volume":"102","author":"Likhitsup","year":"2018","journal-title":"Transplantation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals","volume":"13","author":"Wang","year":"2011","journal-title":"Genet. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jama.1975.03250020022018","article-title":"Advisory Committee to the Renal Transplant Registry. Renal transplantation in Congenital and Metabolic Diseases A report from the ASC\/NIH Renal Transplant Registry","volume":"232","author":"Barnes","year":"1975","journal-title":"JAMA"},{"key":"ref_26","first-page":"57","article-title":"Ten-year experience in renal transplantation for Fabry\u2019s disease","volume":"13","author":"Maizel","year":"1981","journal-title":"Transplant. Proc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry\u2019s disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/TP.0000000000002252","article-title":"Long-term Outcomes of Kidney Transplantation in Fabry Disease","volume":"102","author":"Desnick","year":"2018","journal-title":"Transplantation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A Phase 1\/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety Studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry Disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: A pilot study","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","article-title":"Agalsidase therapy in patients with Fabry disease on renal replacement therapy: A nationwide study in Italy","volume":"23","author":"Mignani","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","article-title":"Kidney transplantation in patients with Fabry disease","volume":"22","author":"Cybulla","year":"2009","journal-title":"Transpl. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000362492","article-title":"Importance of vascular calcification in kidney transplant recipients","volume":"39","author":"Cianciolo","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/TP.0b013e3182a2b492","article-title":"Incidence and predictors of postoperative atrial fibrillation in kidney transplant recipients","volume":"96","author":"Boriani","year":"2013","journal-title":"Transplantation"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Warnock, D.G., Bichet, D.G., Holida, M., Goker-Alpan, O., Nicholls, K., Thomas, M., Eyskens, F., Shankar, S., Adera, M., and Sitaraman, S. (2015). Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active \u03b1-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134341"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year","volume":"105","author":"Gensler","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.5301\/pocj.5000203","article-title":"The management of Fabry nephropathy","volume":"2","author":"Mignani","year":"2016","journal-title":"Nephrol. Point Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfs526","article-title":"Fabry nephropathy: Indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice","volume":"28","author":"Terryn","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Goyal","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J. Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00007890-199104000-00004","article-title":"Recurrence of Fabry\u2019s disease in a renal allograft eleven years after successful renal transplantation","volume":"51","author":"Mosnier","year":"1991","journal-title":"Transplantation"},{"key":"ref_45","first-page":"287","article-title":"Recurrence of Fabry\u2019s disease in a renal allograft 14 years after transplantation","volume":"10","author":"Gantenbein","year":"1995","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bmj.3.5870.28","article-title":"Kidney Transplantation in Fabry\u2019s Disease","volume":"3","author":"Thiel","year":"1973","journal-title":"Br. Med. J."},{"key":"ref_47","first-page":"247","article-title":"Light- and electron-microscopic histochemistry of Fabry\u2019s disease","volume":"103","author":"Faraggiana","year":"1981","journal-title":"Am. J. Pathol."},{"key":"ref_48","first-page":"42A","article-title":"Pseudo recurrence of Fabry\u2019s disease in renal allograft (Abstract)","volume":"54","author":"MacMahon","year":"1986","journal-title":"Lab. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/014107688207500716","article-title":"Renal transplantation in Anderson-Fabry disease","volume":"75","author":"Clement","year":"1982","journal-title":"J. R. Soc. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000167493","article-title":"Involvement of renal allograft by Fabry\u2019s disease","volume":"7","author":"Popli","year":"1987","journal-title":"Am. J. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0041-1345(98)00071-2","article-title":"A case of Fabry\u2019s disease with normal kidney function at 10 years after successful renal transplantation","volume":"30","author":"Erten","year":"1998","journal-title":"Transplant. Proc."},{"key":"ref_52","first-page":"206","article-title":"Renal biopsy in Fabry\u2019s disease eight years after successful renal transplantation","volume":"27","author":"Friedlaender","year":"1987","journal-title":"Clin. Nephrol."},{"key":"ref_53","first-page":"1742","article-title":"Fabry\u2019s disease. Light and electron microscopic cardiac findings 12 years after successful kidney transplantation","volume":"112","author":"Bannwart","year":"1982","journal-title":"Schweiz. Med. Wochenschr."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/6\/284\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:37:36Z","timestamp":1760175456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/6\/284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["medicina56060284"],"URL":"https:\/\/doi.org\/10.3390\/medicina56060284","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]}}}